Skip to main content
. 2021 Jan 11;18(1):e1003454. doi: 10.1371/journal.pmed.1003454

Fig 1. Patient disposition.

Fig 1

ASCT, autologous stem cell transplantation; CR, complete response; CVD, cyclophosphamide, bortezomib, and dexamethasone; KRdc, carfilzomib, lenalidomide, dexamethasone, and cyclophosphamide; MR, minimal response; PD, progressive disease; PR, partial response; Rdc, lenalidomide, dexamethasone, and cyclophosphamide; SD, stable disease; Tdc, thalidomide, dexamethasone, and cyclophosphamide; VGPR, very good partial response.